Search Within

Malin Lisa Hultcrantz

  1. "Department of Pathology and Laboratory Medicine"
Formats
  1. Meeting Abstract (38)
  2. Journal Article (21)
  3. Research Letter (2)
  4. Correspondence (1)
Groups
  1. Center for Hematologic Malignancies (62)
  2. Department of Medicine (62)
  3. Department of Pathology and Laboratory Medicine (62)
  4. Hematologic Malignancies, Division of (62)
  5. Myeloma (62)
  6. Sloan Kettering Institute Postdocs (62)

More Groups

People
  1. Sham Mailankody (46)
  2. Alexander Lesokhin (45)
  3. Neha Korde (44)
  4. Hani Hassoun (42)
  5. Heather Landau (41)
  6. Urvi Shah (39)

More People

Years
  1. 2025 (1)
  2. 2024 (7)
  3. 2023 (11)
  4. 2022 (6)
  5. 2021 (10)
  6. 2020 (11)

More Years

Publications
  1. Blood (28)
  2. Clinical Lymphoma, Myeloma and Leukemia (9)
  3. Blood Cancer Journal (3)
  4. Journal of Clinical Oncology (3)
  5. Nature Communications (3)
  6. American Journal of Hematology (2)

More Publications

Publishers
  1. American Society of Hematology (29)
  2. Elsevier Inc. (10)
  3. Nature Publishing Group (6)
  4. American Association for Cancer Research (3)
  5. American Society of Clinical Oncology (3)
  6. American Medical Association (2)

More Publishers

Results (62)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Long-term sustained minimal residual disease (MRD) negativity in patients with multiple myeloma treated with continuous lenalidomide maintenance therapy: A clinical and correlative phase 2 study
    Meeting Abstract

    Diamond, B.; Korde, N.; Lesokhin, A. M.; Smith, E. L.; Shah, U. A.; Mailankody, S.; Hultcrantz, M.; Hassoun, H.; Lu, S. X.; Tan, C.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Initial whole genome sequencing of plasma cell neoplasms in first responders and recovery workers exposed to the World Trade Center attack of September 11, 2001
    Meeting Abstract

    Diamond, B.; Maclachlan, K. H.; Derkach, A.; Yellapantula, V.; Rustad, E. H.; Hultcrantz, M.; Shah, U. A.; Hong, J.; Landau, H. J.; Iacobuzio-Donahue, C.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Stem cell mobilization and autograft minimal residual disease negativity with novel induction regimens in multiple myeloma
    Journal Article

    Bal, S.; Landau, H. J.; Shah, G. L.; Scordo, M.; Dahi, P.; Lahoud, O. B.; Hassoun, H.; Hultcrantz, M.; Korde, N.; Lendvai, N.; more...
    Biology of Blood and Marrow Transplantation (2020)

    Fulltext@MSK | Save
  • Accelerated single cell seeding in relapsed multiple myeloma
    Journal Article

    Landau, H. J.; Yellapantula, V.; Diamond, B. T.; Rustad, E. H.; Maclachlan, K. H.; Gundem, G.; Medina-Martinez, J.; Arango Ossa, J.; Levine, M. F.; Zhou, Y.; more...
    Nature Communications (2020)

    Fulltext@MSK | Save
  • Baseline VDJ clonotype detection using a targeted sequencing NGS assay: Allowing for subsequent MRD assessment
    Research Letter

    Hultcrantz, M.; Rustad, E. H.; Yellapantula, V.; Arcila, M.; Ho, C.; Syed, M. H.; Papaemmanuil, E.; Zhang, Y.; Maura, F.; Landgren, O.
    Blood Cancer Journal (2020)

    Fulltext@MSK | Save
  • Comparison of MALDI-TOF mass spectrometry analysis of peripheral blood and bone marrow-based flow cytometry for tracking measurable residual disease in patients with multiple myeloma
    Journal Article

    Eveillard, M.; Rustad, E.; Roshal, M.; Zhang, Y.; Ciardiello, A.; Korde, N.; Hultcrantz, M.; Lu, S.; Shah, U.; Hassoun, H.; more...
    British Journal of Haematology (2020)

    Fulltext@MSK | Save
  • Long-term sustained minimal residual disease (MRD) negativity in multiple myeloma patients treated with lenalidomide maintenance therapy: A clinical and correlative phase 2 study
    Meeting Abstract

    Landgren, O.; Mastey, D.; Lesokhin, A. M.; Smith, E. L.; Shah, U. A.; Mailankody, S.; Hultcrantz, M.; Hassoun, H.; Lu, S. X.; Salcedo, M.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Comparison of MALDI-TOF mass spectrometry analysis of peripheral blood and bone marrow based flow cytometry for tracking measurable residual disease (MRD) in patients with multiple myeloma
    Meeting Abstract

    Eveillard, M.; Rustad, E. H.; Roshal, M.; Zhang, Y.; Ciardiello, A. K.; Korde, N.; Hultcrantz, M.; Hassoun, H.; Smith, E. L.; Lesokhin, A. M.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Weekly carfilzomib, lenalidomide, dexamethasone and daratumumab (wKRd-D) combination therapy provides unprecedented MRD negativity rates in newly diagnosed multiple myeloma: A clinical and correlative phase 2 study
    Meeting Abstract

    Landgren, O.; Hultcrantz, M.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; Smith, E. L.; Shah, U. A.; Lu, S. X.; Mastey, D.; Salcedo, M.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Comprehensive detection of recurring genomic abnormalities: A targeted sequencing approach for multiple myeloma
    Journal Article

    Yellapantula, V.; Hultcrantz, M.; Rustad, E. H.; Wasserman, E.; Londono, D.; Cimera, R.; Ciardiello, A.; Landau, H.; Akhlaghi, T.; Mailankody, S.; more...
    Blood Cancer Journal (2019)

    Fulltext@MSK | Save